Question 1

How is a PMA different from a 510(k)?

Accepted Answer

A 510(k) clears a device by demonstrating substantial equivalence to a legally marketed predicate. A PMA is the most stringent FDA device pathway: it applies to Class III devices and requires independent demonstration of reasonable assurance of safety and effectiveness, usually through clinical data, rather than comparison to a predicate. Assyro helps teams keep the larger PMA evidence base — clinical, nonclinical, manufacturing, and labeling — coordinated and audit-ready.

Question 2

Does Assyro support modular PMA submissions?

Accepted Answer

Yes. Many sponsors file a PMA in modules (for example nonclinical, then manufacturing, then clinical) so FDA can review sections as they are completed. Assyro keeps each module's content, owners, and dependencies aligned with the overall submission so the modular shell does not drift out of sync as study data and CMC evolve.

Question 3

Can Assyro help with PMA deficiency responses?

Accepted Answer

Yes. PMA review commonly includes deficiency and major-deficiency letters that must be answered with specific evidence under time pressure. Assyro keeps the supporting clinical, manufacturing, and labeling evidence linked and traceable so responses are assembled from the existing dossier instead of rebuilt from scratch.

Question 4

When should we bring Assyro into the PMA process?

Accepted Answer

As early as possible. Teams get the most value when PMA workflows are in place before the final lock window, while owners are still drafting, reviewing, validating, and resolving issues. That is how teams avoid clinical, nonclinical, manufacturing, and labeling evidence live in separate systems with no single readiness view.

Question 5

Which functions usually collaborate in the PMA workflow?

Accepted Answer

PMA programs usually require Regulatory Affairs, Regulatory Operations, QA, CMC, Clinical, Medical, or device stakeholders depending on the filing type. Assyro keeps those teams working in one tracked execution layer instead of coordinating across disconnected tools.

Question 6

How does Assyro reduce rework in PMA submissions?

Accepted Answer

Assyro reduces rework by making readiness visible earlier, routing work to the right owners, and keeping evidence, review decisions, and validation context connected. The goal is to organize the full pma dossier — clinical, nonclinical, cmc, and labeling — in one traceable execution layer instead of discovering blockers at the end.

Question 7

Can Assyro support post-filing updates, agency questions, or follow-on lifecycle work after the initial PMA?

Accepted Answer

Yes. Teams use the same workflow model to manage post-filing questions, amendments, supplements, or other follow-on actions with traceable decisions and linked prior context. That keeps the program history usable instead of rebuilding it every cycle.

Question 8

How does Assyro help with traceability and audit readiness for PMA work?

Accepted Answer

Assyro keeps owners, status, validation findings, and decision rationale connected inside the workflow so every PMA filing step is easier to explain and defend. That matters for teams operating against 21 CFR Part 814 and 21 CFR Part 820.

Question 9

Can we start on one active PMA program before rolling it out more broadly?

Accepted Answer

Yes. Many teams start with a single live PMA program, map the current bottlenecks, and use that as the proof point for a broader rollout. That keeps implementation practical while still showing measurable gains in time, quality, and rework reduction.

PMA Submission Software

PMA Filing Workflow

Go From 3 Weeks of Review Cycles to 48 Hours

Stop Losing Documents Between 5 Different Systems

Know Your Exact Readiness Score at Any Moment

Never Miss a Submission Deadline Again

PMA Filing Controls and Capacity

Maintain Audit-Ready PMA Records

Manage More PMA Programs With the Same Team Size

Questions About PMA Submission Software

See PMA on Your Next Filing.